Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration ...

Scientists have designed new drug frameworks that selectively target CYP3A4, one of the most critical CYP proteins.

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.